UA76104C2 - Use of lactic acid bacteria, in particular lactobacillus johnsonii cncm 1-1225, lactobacillus paracasei cncm 1-2116 or bifidobacterium cncm 1-2168 for preventing peritonitis - Google Patents
Use of lactic acid bacteria, in particular lactobacillus johnsonii cncm 1-1225, lactobacillus paracasei cncm 1-2116 or bifidobacterium cncm 1-2168 for preventing peritonitis Download PDFInfo
- Publication number
- UA76104C2 UA76104C2 UA2002108396A UA2002108396A UA76104C2 UA 76104 C2 UA76104 C2 UA 76104C2 UA 2002108396 A UA2002108396 A UA 2002108396A UA 2002108396 A UA2002108396 A UA 2002108396A UA 76104 C2 UA76104 C2 UA 76104C2
- Authority
- UA
- Ukraine
- Prior art keywords
- peritonitis
- lactic acid
- acid bacteria
- cncm
- carrier
- Prior art date
Links
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title claims abstract description 46
- 241000894006 Bacteria Species 0.000 title claims abstract description 33
- 206010034674 peritonitis Diseases 0.000 title claims abstract description 25
- 239000004310 lactic acid Substances 0.000 title claims abstract description 23
- 235000014655 lactic acid Nutrition 0.000 title claims abstract description 23
- 241000186000 Bifidobacterium Species 0.000 title 1
- 241001468157 Lactobacillus johnsonii Species 0.000 title 1
- 241000186605 Lactobacillus paracasei Species 0.000 title 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims abstract description 12
- 206010016654 Fibrosis Diseases 0.000 claims description 9
- 230000001580 bacterial effect Effects 0.000 claims description 9
- 230000007882 cirrhosis Effects 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 6
- 206010062070 Peritonitis bacterial Diseases 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 5
- 210000004347 intestinal mucosa Anatomy 0.000 claims description 5
- 235000015140 cultured milk Nutrition 0.000 claims description 4
- 239000008267 milk Substances 0.000 claims description 4
- 235000013336 milk Nutrition 0.000 claims description 4
- 210000004080 milk Anatomy 0.000 claims description 4
- 238000000502 dialysis Methods 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 235000013351 cheese Nutrition 0.000 claims description 2
- 235000015243 ice cream Nutrition 0.000 claims description 2
- 235000016709 nutrition Nutrition 0.000 claims description 2
- 230000035764 nutrition Effects 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000013589 supplement Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 235000013618 yogurt Nutrition 0.000 claims description 2
- 235000013350 formula milk Nutrition 0.000 claims 2
- 235000021542 oral nutrition Nutrition 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 32
- 210000000936 intestine Anatomy 0.000 abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 208000035475 disorder Diseases 0.000 abstract description 3
- 210000004877 mucosa Anatomy 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 244000005700 microbiome Species 0.000 description 10
- 210000000987 immune system Anatomy 0.000 description 7
- 210000004303 peritoneum Anatomy 0.000 description 7
- 206010003445 Ascites Diseases 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 210000001165 lymph node Anatomy 0.000 description 6
- 210000003567 ascitic fluid Anatomy 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 210000004910 pleural fluid Anatomy 0.000 description 5
- 206010070545 Bacterial translocation Diseases 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 230000007375 bacterial translocation Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 244000000010 microbial pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 3
- 229960002695 phenobarbital Drugs 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000305071 Enterobacterales Species 0.000 description 2
- 206010019663 Hepatic failure Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000012868 Overgrowth Diseases 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 210000004534 cecum Anatomy 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002350 laparotomy Methods 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 208000007903 liver failure Diseases 0.000 description 2
- 231100000835 liver failure Toxicity 0.000 description 2
- 210000003240 portal vein Anatomy 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 101000587455 Homo sapiens Single-stranded DNA-binding protein, mitochondrial Proteins 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 240000002129 Malva sylvestris Species 0.000 description 1
- 235000006770 Malva sylvestris Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108700022034 Opsonin Proteins Proteins 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 102100029719 Single-stranded DNA-binding protein, mitochondrial Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008952 bacterial invasion Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- -1 for example Substances 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000011200 hepatorenal syndrome Diseases 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000012543 microbiological analysis Methods 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 235000011649 selenium Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000016804 zinc Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/151—Johnsonii
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/853—Lactobacillus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Dairy Products (AREA)
- Confectionery (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00106441 | 2000-03-24 | ||
PCT/EP2001/003271 WO2001070246A1 (en) | 2000-03-24 | 2001-03-22 | Use of lactic acid bacterium for the treatment of peritonitis |
Publications (1)
Publication Number | Publication Date |
---|---|
UA76104C2 true UA76104C2 (en) | 2006-07-17 |
Family
ID=8168228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UA2002108396A UA76104C2 (en) | 2000-03-24 | 2001-03-22 | Use of lactic acid bacteria, in particular lactobacillus johnsonii cncm 1-1225, lactobacillus paracasei cncm 1-2116 or bifidobacterium cncm 1-2168 for preventing peritonitis |
Country Status (22)
Country | Link |
---|---|
US (2) | US7217414B2 (es) |
EP (1) | EP1276488B1 (es) |
JP (1) | JP2003527432A (es) |
KR (1) | KR20020087418A (es) |
CN (1) | CN1183916C (es) |
AR (1) | AR028288A1 (es) |
AT (1) | ATE348626T1 (es) |
AU (1) | AU783439C (es) |
BG (1) | BG107096A (es) |
BR (1) | BR0109496A (es) |
CA (1) | CA2403491A1 (es) |
DE (1) | DE60125345T2 (es) |
ES (1) | ES2276793T3 (es) |
HK (1) | HK1052465B (es) |
HU (1) | HUP0301059A3 (es) |
IL (2) | IL151596A0 (es) |
MX (1) | MXPA02009342A (es) |
NO (1) | NO20024488L (es) |
PL (1) | PL358214A1 (es) |
UA (1) | UA76104C2 (es) |
WO (1) | WO2001070246A1 (es) |
ZA (1) | ZA200208592B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100845456B1 (ko) * | 2001-02-06 | 2008-07-10 | 소시에떼 데 프로듀이 네슬레 소시에떼아노님 | 젖산균 및 비피도균에 의한 내독소 결합 |
DE60231809D1 (es) * | 2001-02-19 | 2009-05-14 | Nestle Sa | |
JP2005526038A (ja) * | 2002-02-21 | 2005-09-02 | ソシエテ デ プロデユイ ネツスル ソシエテ アノニム | 皮膚の光防護のための経口投与可能な組成物 |
JP2005517419A (ja) * | 2002-02-21 | 2005-06-16 | ソシエテ デ プロデユイ ネツスル ソシエテ アノニム | 皮膚の光防護に適するペットフード組成物 |
DE60317646T2 (de) * | 2002-02-21 | 2008-10-30 | Société des Produits Nestlé S.A. | Photoprotektive oral verabreichbare zusammensetzung für die haut |
EP1384483A1 (en) * | 2002-07-23 | 2004-01-28 | Nestec S.A. | Probiotics for treatment of irritable bowel disease (IBS) through improvement of gut neuromuscular function |
DK2277524T3 (en) | 2005-09-28 | 2016-02-08 | Nordisk Rebalance As | Treatment of IBS using both probiotic bacteria and fermented cereal as treatment effectors |
EP1992351B1 (en) * | 2007-05-18 | 2016-05-11 | Nestec S.A. | Lactobacillus johnsonii for prevention of postsurgical infection |
EP2123168B1 (en) * | 2008-05-16 | 2011-12-21 | Nestec S.A. | Lactobacillus paracasei and weight control |
RU2556124C2 (ru) * | 2009-05-11 | 2015-07-10 | Нестек С.А. | Lactobacillus johnsonii La1 NСС533 (CNCM 1-1225) И ИММУННЫЕ НАРУШЕНИЯ |
GB0914878D0 (en) | 2009-08-26 | 2009-09-30 | Plant Bioscience Ltd | Competetive exclusion compositions and methods |
CN105816484A (zh) * | 2015-01-07 | 2016-08-03 | 东宇生物科技股份有限公司 | 用于腹膜透析病患预防腹膜炎并减少肾功能恶化的组合物 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU1723116A1 (ru) * | 1988-04-15 | 1992-03-30 | Оренбургский Государственный Медицинский Институт | Штамм бактерий BacILLUS SUвтILIS, используемый дл получени препарата дл профилактики и лечени воспалительных процессов и аллергических заболеваний |
JPH04264034A (ja) | 1991-02-18 | 1992-09-18 | Snow Brand Milk Prod Co Ltd | 生体内過酸化脂質抑制剤 |
US5716615A (en) * | 1992-02-10 | 1998-02-10 | Renata Maria Anna Cavaliere Vesely | Dietary and pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use |
DE69219768T2 (de) * | 1992-07-06 | 1997-08-28 | Societe Des Produits Nestle S.A., Vevey | Milchbakterien |
JP2712000B2 (ja) | 1994-12-22 | 1998-02-10 | ニチニチ製薬株式会社 | C型肝炎治療剤 |
SE9501719D0 (sv) | 1995-05-09 | 1995-05-09 | Probi Ab | Pharmaceutical composition |
US6562629B1 (en) * | 1999-08-11 | 2003-05-13 | Cedars-Sinai Medical Center | Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum |
JPH09301877A (ja) | 1996-05-13 | 1997-11-25 | Youshindou:Kk | 肝炎治療・予防剤 |
CA2263376C (en) * | 1996-09-06 | 2006-01-17 | Societe Des Produits Nestle S.A. | Overrun ice cream with coating containing lactic bacteria |
PT862863E (pt) * | 1997-01-09 | 2002-04-29 | Nestle Sa | Produto cerealifero contendo probioticos |
IT1289984B1 (it) | 1997-02-27 | 1998-10-19 | Proge Farm Srl | Ceppi di lattobacilli utili nel trattamento di disfunzioni del sistema gastrointestinale |
WO1999002042A2 (fr) * | 1997-07-05 | 1999-01-21 | Societe Des Produits Nestle S.A. | Dessert congele contenant des bacteries lactiques et des fibres fermentescibles |
RO112995B1 (ro) * | 1997-08-05 | 1998-03-30 | Rodica Teodorescu | Produs medicamentos pentru terapia colonului |
US6368591B2 (en) * | 1998-05-15 | 2002-04-09 | Shanghai Sine Pharmaceutical Corporation Ltd. | Beneficial microbe composition, new protective materials for the microbes, method to prepare the same and uses thereof |
-
2001
- 2001-03-22 BR BR0109496-3A patent/BR0109496A/pt not_active Application Discontinuation
- 2001-03-22 CA CA002403491A patent/CA2403491A1/en not_active Abandoned
- 2001-03-22 EP EP01936125A patent/EP1276488B1/en not_active Expired - Lifetime
- 2001-03-22 KR KR1020027012250A patent/KR20020087418A/ko not_active Application Discontinuation
- 2001-03-22 AU AU62127/01A patent/AU783439C/en not_active Ceased
- 2001-03-22 JP JP2001568443A patent/JP2003527432A/ja active Pending
- 2001-03-22 ES ES01936125T patent/ES2276793T3/es not_active Expired - Lifetime
- 2001-03-22 UA UA2002108396A patent/UA76104C2/uk unknown
- 2001-03-22 PL PL01358214A patent/PL358214A1/xx unknown
- 2001-03-22 CN CNB018071198A patent/CN1183916C/zh not_active Expired - Fee Related
- 2001-03-22 DE DE60125345T patent/DE60125345T2/de not_active Expired - Lifetime
- 2001-03-22 AT AT01936125T patent/ATE348626T1/de not_active IP Right Cessation
- 2001-03-22 IL IL15159601A patent/IL151596A0/xx unknown
- 2001-03-22 WO PCT/EP2001/003271 patent/WO2001070246A1/en active Application Filing
- 2001-03-22 MX MXPA02009342A patent/MXPA02009342A/es active IP Right Grant
- 2001-03-22 HU HU0301059A patent/HUP0301059A3/hu unknown
- 2001-03-26 AR ARP010101403A patent/AR028288A1/es unknown
-
2002
- 2002-09-04 IL IL151596A patent/IL151596A/en not_active IP Right Cessation
- 2002-09-12 BG BG107096A patent/BG107096A/bg unknown
- 2002-09-19 NO NO20024488A patent/NO20024488L/no not_active Application Discontinuation
- 2002-09-20 US US10/247,841 patent/US7217414B2/en not_active Expired - Fee Related
- 2002-10-23 ZA ZA200208592A patent/ZA200208592B/en unknown
-
2003
- 2003-07-07 HK HK03104806.3A patent/HK1052465B/zh not_active IP Right Cessation
-
2007
- 2007-04-06 US US11/697,518 patent/US7678370B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
HUP0301059A3 (en) | 2004-10-28 |
MXPA02009342A (es) | 2003-09-22 |
US20030044397A1 (en) | 2003-03-06 |
DE60125345D1 (de) | 2007-02-01 |
HK1052465B (zh) | 2007-05-11 |
HK1052465A1 (en) | 2003-09-19 |
NO20024488D0 (no) | 2002-09-19 |
EP1276488A1 (en) | 2003-01-22 |
US20070172512A1 (en) | 2007-07-26 |
CN1419454A (zh) | 2003-05-21 |
BG107096A (bg) | 2003-05-30 |
NO20024488L (no) | 2002-09-19 |
US7217414B2 (en) | 2007-05-15 |
DE60125345T2 (de) | 2007-09-27 |
CA2403491A1 (en) | 2001-09-27 |
AU6212701A (en) | 2001-10-03 |
IL151596A0 (en) | 2003-04-10 |
ATE348626T1 (de) | 2007-01-15 |
JP2003527432A (ja) | 2003-09-16 |
BR0109496A (pt) | 2002-12-10 |
PL358214A1 (en) | 2004-08-09 |
IL151596A (en) | 2008-07-08 |
HUP0301059A2 (hu) | 2003-07-28 |
EP1276488B1 (en) | 2006-12-20 |
US7678370B2 (en) | 2010-03-16 |
CN1183916C (zh) | 2005-01-12 |
AR028288A1 (es) | 2003-04-30 |
AU783439C (en) | 2006-12-14 |
AU783439B2 (en) | 2005-10-27 |
KR20020087418A (ko) | 2002-11-22 |
WO2001070246A1 (en) | 2001-09-27 |
ES2276793T3 (es) | 2007-07-01 |
ZA200208592B (en) | 2004-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hudault et al. | Antagonistic activity exerted in vitro and in vivo by Lactobacillus casei (strain GG) against Salmonella typhimurium C5 infection | |
Mombelli et al. | The use of probiotics in medical practice | |
ES2232869T3 (es) | Tratamiento contra la diarrea. | |
US7678370B2 (en) | Methods of preventing peritonitis by administering lactic acid bacterium | |
Ayichew et al. | Bacterial probiotics their importances and limitations: a review | |
EP1162987B1 (en) | Pharmaceutical composition for medical and veterinary use for regenerating intestinal flora in diarrhoea or dyspeptic syndrome | |
Wiest et al. | Effect of Lactobacillus-fermented diets on bacterial translocation and intestinal flora in experimental prehepatic portal hypertension | |
WO1999017788A1 (en) | Composition of treatment of candidiasis | |
CA2570062C (en) | Lactic bacteria and their use in the prevention of diarrhea | |
Penna et al. | Up-to-date clinical and experimental basis for the use of probiotics | |
JP2001048796A (ja) | 感染症予防機能及び免疫関連疾患の軽減機能を有する腸内細菌由来乳酸菌エキス及び死菌体粉末とその食品応用 | |
RU2400235C1 (ru) | Способ лечения больных с дисбактериозом кишечника | |
Lima-Filho et al. | Effect of the Escherichia coli EMO strain on experimental infection by Salmonella enterica serovar Typhimurium in gnotobiotic mice | |
El-Jakee et al. | Influence of probiotics mixture on Salmonella typhimurium in mice | |
RU2123345C1 (ru) | Средство для лечения дисбактериоза | |
Shukla et al. | Role of Probiotics on Gut Microflora | |
RU2571495C1 (ru) | Способ лечения больных дисбактериозом кишечника | |
Baker | Atopic disease-the role of probiotics | |
AU706968B2 (en) | Treatment of bowel-dependent neurological disorders | |
De Petrino et al. | Influence of the oral administration of different lactic acid bacteria on intestinal microflora and iga‐secreting cells in mice treated with ampicillin | |
Hayes | Bovine colostrum | |
Baker | Atopic disease: is there a role for probiotics in the management of this chronic disorder? | |
Kroeker et al. | Treatment of Ulcerative Colitis | |
HUDAULT | EVOLUTION OF THE INTESTINAL MICROFLORA OF NEONATES | |
Zhou | Safety studies on probiotic strains Lactobacillus rhamnosus HN001, Lactobacillus acidophilus HN017, and Bifidobacterium lactis HN019: a thesis submitted for the degree of Doctor of Philosophy at Massey University, Palmerston North, New Zealand |